Insider Trading Alert - CTIC, KR And IBKR Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, March 28, 2014, 73 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $105.75 to $179,310,826.89.

Highlighted Stocks Traded by Insiders:

Cell Therapeutics (CTIC) - FREE Research Report

Gregorian Vartan who is Director at Cell Therapeutics sold 82,000 shares at $3.41 on March 28, 2014. Following this transaction, the Director owned 468,937 shares meaning that the stake was reduced by 14.88% with the 82,000-share transaction.

The shares most recently traded at $3.42, up $0.01, or 0.23% since the insider transaction. Historical insider transactions for Cell Therapeutics go as follows:

  • 4-Week # shares sold: 962,095
  • 12-Week # shares sold: 962,095
  • 24-Week # shares sold: 968,095

The average volume for Cell Therapeutics has been 6.6 million shares per day over the past 30 days. Cell Therapeutics has a market cap of $514.8 million and is part of the health care sector and drugs industry. Shares are up 80.1% year-to-date as of the close of trading on Friday.

Cell Therapeutics, Inc. acquires, develops, and commercializes treatments for cancer. Currently there are 2 analysts that rate Cell Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CTIC - FREE

TheStreet Quant Ratings rates Cell Therapeutics as a sell. The area that we feel has been the company's primary weakness has been its disappointing return on equity. Get the full Cell Therapeutics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Kroger (KR) - FREE Research Report

Covert Geoffrey J who is Senior Vice President at Kroger sold 13,000 shares at $43.23 on March 28, 2014. Following this transaction, the Senior Vice President owned 87,934 shares meaning that the stake was reduced by 12.88% with the 13,000-share transaction.

The shares most recently traded at $43.78, up $0.55, or 1.27% since the insider transaction. Historical insider transactions for Kroger go as follows:

  • 4-Week # shares sold: 8,000
  • 12-Week # shares sold: 8,000
  • 24-Week # shares sold: 18,000

The average volume for Kroger has been 4.5 million shares per day over the past 30 days. Kroger has a market cap of $22.5 billion and is part of the services sector and retail industry. Shares are up 11.18% year-to-date as of the close of trading on Friday.

The Kroger Co., together with its subsidiaries, operates as a retailer in the United States. The company also manufactures and processes food for sale in its supermarkets. It operates retail food and drug stores, multi-department stores, jewelry stores, and convenience stores. The stock currently has a dividend yield of 1.5%. The company has a P/E ratio of 15.4. Currently there are 7 analysts that rate Kroger a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KR - FREE

TheStreet Quant Ratings rates Kroger as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Kroger Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Interactive Brokers Group (IBKR) - FREE Research Report

Galik Milan who is SVP Software Development at Interactive Brokers Group sold 1,800 shares at $21.44 on March 28, 2014. Following this transaction, the SVP Software Development owned 792,317 shares meaning that the stake was reduced by 0.23% with the 1,800-share transaction.

The shares most recently traded at $21.38, down $0.06, or 0.28% since the insider transaction. Historical insider transactions for Interactive Brokers Group go as follows:

  • 4-Week # shares sold: 14,400
  • 12-Week # shares sold: 49,400
  • 24-Week # shares sold: 104,400

The average volume for Interactive Brokers Group has been 520,500 shares per day over the past 30 days. Interactive Brokers Group has a market cap of $1.1 billion and is part of the financial sector and financial services industry. Shares are down 12.86% year-to-date as of the close of trading on Friday.

Interactive Brokers Group, Inc. operates as an automated electronic broker and market maker. The stock currently has a dividend yield of 1.82%. The company has a P/E ratio of 30.0. Currently there are 3 analysts that rate Interactive Brokers Group a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on IBKR - FREE

TheStreet Quant Ratings rates Interactive Brokers Group as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and reasonable valuation levels. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Interactive Brokers Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
null

If you liked this article you might like

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Insider Trading Alert - LPNT, PATK And CTIC Traded By Insiders

Insider Trading Alert - LPNT, PATK And CTIC Traded By Insiders

Insider Trading Alert - SPTN, FL And CTIC Traded By Insiders

Insider Trading Alert - SPTN, FL And CTIC Traded By Insiders